At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 356 enrolled
Drug / intervention
Mitoglitazone +4 moredrug
Likely dose
Mitoglitazone 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2B, Randomized, Double-Blind, Comparator- & Placebo-Controlled, Dose Ranging Study to Evaluate Safety, Tolerability & Efficacy of 3 Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
In Brief
A Phase 2 clinical trial evaluating Mitoglitazone, Pioglitazone, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 356 participants across 24 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of three dose levels of Mitoglitazone™ (MSDC-0160) in patients with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartSep 2010
Primary CompletionNov 2011
Study CompletionDec 2011
TodayJul 2026
First PostedApr 14, 2010
Enrollment StartSep 1, 2010
Primary CompletionNov 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.2 years ago
Interventions
Mitoglitazonedrug
50 mg capsules, once daily for 84 days
Mitoglitazonedrug
Mitoglitazone 100 mg capsules, once daily for 84 days
Mitoglitazonedrug
Mitoglitazone 150 mg capsules, once daily for 84 days
Pioglitazonedrug
Pioglitazone 45 mg, once daily for 84 days
Placebodrug
Placebo, once daily for 84 days